Birdwatch Note
2024-08-05 12:56:03 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
個人輸入による医薬品では偽造薬などの問題があり品質や安全面でのリスクがあります。 個人輸入の医薬品による有害事象は医薬品副作用救済制度の対象外であることに注意が必要です。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/kojinyunyu/index.html パキシジェンは日本国において未承認薬であるため医薬品副作用救済制度の対象外になる可能性もあります。 https://www.jpma.or.jp/about_medicine/guide/med_qa/q52.html また抗ウイルス薬の不適切な使用(常備しておき確定診断がない状態で服用するなど)は薬剤耐性ウイルスの誘導により有効な治療手段を失わせてしまうリスクがあります。 https://www.forth.go.jp/moreinfo/topics/2017/11211141.html
Written by 9C59FAB7FC7494941C94F91C98D72EC62BFE546F6382D6F374B56B6ABDB5F92C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1820387274061938766
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1820443650452848872
- noteId - 1820443650452848872
- participantId -
- noteAuthorParticipantId - 9C59FAB7FC7494941C94F91C98D72EC62BFE546F6382D6F374B56B6ABDB5F92C Participant Details
- createdAtMillis - 1722862563131
- tweetId - 1820387274061938766
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 個人輸入による医薬品では偽造薬などの問題があり品質や安全面でのリスクがあります。 個人輸入の医薬品による有害事象は医薬品副作用救済制度の対象外であることに注意が必要です。 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/kojinyunyu/index.html パキシジェンは日本国において未承認薬であるため医薬品副作用救済制度の対象外になる可能性もあります。 https://www.jpma.or.jp/about_medicine/guide/med_qa/q52.html また抗ウイルス薬の不適切な使用(常備しておき確定診断がない状態で服用するなど)は薬剤耐性ウイルスの誘導により有効な治療手段を失わせてしまうリスクがあります。 https://www.forth.go.jp/moreinfo/topics/2017/11211141.html
Note Ratings
rated at | rated by | |
2024-08-07 04:40:08 -0500 | Rating Details | |
2024-08-06 20:47:00 -0500 | Rating Details | |
2024-08-06 20:37:15 -0500 | Rating Details | |
2024-08-06 19:12:10 -0500 | Rating Details | |
2024-08-06 18:34:34 -0500 | Rating Details | |
2024-08-06 16:59:03 -0500 | Rating Details | |
2024-08-06 10:33:49 -0500 | Rating Details | |
2024-08-06 10:31:29 -0500 | Rating Details | |
2024-08-06 08:52:16 -0500 | Rating Details | |
2024-08-06 08:47:39 -0500 | Rating Details | |
2024-08-06 08:22:16 -0500 | Rating Details | |
2024-08-06 07:56:22 -0500 | Rating Details | |
2024-08-06 07:31:29 -0500 | Rating Details | |
2024-08-06 07:14:20 -0500 | Rating Details | |
2024-08-06 06:56:09 -0500 | Rating Details | |
2024-08-06 06:46:31 -0500 | Rating Details | |
2024-08-06 05:05:30 -0500 | Rating Details | |
2024-08-06 04:55:31 -0500 | Rating Details | |
2024-08-06 04:49:00 -0500 | Rating Details | |
2024-08-06 04:25:22 -0500 | Rating Details | |
2024-08-06 03:57:56 -0500 | Rating Details | |
2024-08-06 03:37:37 -0500 | Rating Details | |
2024-08-06 03:06:01 -0500 | Rating Details | |
2024-08-06 02:46:50 -0500 | Rating Details | |
2024-08-06 02:15:49 -0500 | Rating Details | |
2024-08-06 01:30:11 -0500 | Rating Details | |
2024-08-06 01:16:14 -0500 | Rating Details | |
2024-08-06 00:40:05 -0500 | Rating Details | |
2024-08-06 00:14:35 -0500 | Rating Details | |
2024-08-06 00:13:53 -0500 | Rating Details | |
2024-08-05 23:56:42 -0500 | Rating Details | |
2024-08-05 23:15:38 -0500 | Rating Details | |
2024-08-05 23:01:45 -0500 | Rating Details | |
2024-08-05 21:51:03 -0500 | Rating Details | |
2024-08-05 21:36:41 -0500 | Rating Details | |
2024-08-05 21:16:23 -0500 | Rating Details | |
2024-08-05 20:38:22 -0500 | Rating Details | |
2024-08-05 19:07:55 -0500 | Rating Details | |
2024-08-05 18:59:58 -0500 | Rating Details | |
2024-08-05 18:59:57 -0500 | Rating Details | |
2024-08-05 18:49:04 -0500 | Rating Details | |
2024-08-05 18:40:14 -0500 | Rating Details | |
2024-08-05 18:21:37 -0500 | Rating Details | |
2024-08-05 18:14:50 -0500 | Rating Details | |
2024-08-05 18:07:18 -0500 | Rating Details | |
2024-08-05 17:54:55 -0500 | Rating Details | |
2024-08-05 17:43:24 -0500 | Rating Details | |
2024-08-05 17:34:06 -0500 | Rating Details | |
2024-08-05 17:33:32 -0500 | Rating Details | |
2024-08-05 17:29:17 -0500 | Rating Details | |
2024-08-05 17:19:06 -0500 | Rating Details | |
2024-08-05 17:16:20 -0500 | Rating Details | |
2024-08-05 17:15:47 -0500 | Rating Details | |
2024-08-05 17:07:59 -0500 | Rating Details | |
2024-08-05 16:57:12 -0500 | Rating Details | |
2024-08-05 16:48:28 -0500 | Rating Details | |
2024-08-05 16:35:59 -0500 | Rating Details | |
2024-08-05 16:25:18 -0500 | Rating Details | |
2024-08-05 16:25:15 -0500 | Rating Details | |
2024-08-05 16:20:17 -0500 | Rating Details | |
2024-08-05 14:32:11 -0500 | Rating Details | |
2024-08-05 14:28:52 -0500 | Rating Details | |
2024-08-05 13:51:52 -0500 | Rating Details | |
2024-08-05 13:22:19 -0500 | Rating Details | |
2024-08-05 12:23:30 -0500 | Rating Details | |
2024-08-05 11:57:03 -0500 | Rating Details | |
2024-08-05 11:54:20 -0500 | Rating Details | |
2024-08-05 11:49:52 -0500 | Rating Details | |
2024-08-05 11:24:01 -0500 | Rating Details | |
2024-08-05 11:18:45 -0500 | Rating Details | |
2024-08-05 11:17:46 -0500 | Rating Details | |
2024-08-05 10:17:31 -0500 | Rating Details | |
2024-08-05 10:17:04 -0500 | Rating Details | |
2024-08-05 09:36:14 -0500 | Rating Details | |
2024-08-05 09:34:10 -0500 | Rating Details | |
2024-08-05 09:10:17 -0500 | Rating Details | |
2024-08-05 09:06:21 -0500 | Rating Details | |
2024-08-05 09:02:25 -0500 | Rating Details | |
2024-08-05 08:55:51 -0500 | Rating Details | |
2024-08-05 08:46:29 -0500 | Rating Details | |
2024-08-05 08:45:10 -0500 | Rating Details | |
2024-08-05 08:37:28 -0500 | Rating Details | |
2024-08-05 08:12:36 -0500 | Rating Details | |
2024-08-05 08:06:23 -0500 | Rating Details | |
2024-08-05 08:05:16 -0500 | Rating Details | |
2024-08-05 08:04:37 -0500 | Rating Details | |
2024-08-05 08:02:46 -0500 | Rating Details | |
2024-08-05 08:02:35 -0500 | Rating Details | |
2024-08-10 01:34:19 -0500 | Rating Details | |
2024-08-10 01:20:15 -0500 | Rating Details | |
2024-08-07 05:40:21 -0500 | Rating Details | |
2024-08-07 02:05:08 -0500 | Rating Details | |
2024-08-06 19:15:41 -0500 | Rating Details | |
2024-08-06 18:29:57 -0500 | Rating Details | |
2024-08-06 10:57:25 -0500 | Rating Details | |
2024-08-06 10:42:40 -0500 | Rating Details | |
2024-08-06 10:23:14 -0500 | Rating Details | |
2024-08-06 09:30:29 -0500 | Rating Details | |
2024-08-06 07:19:28 -0500 | Rating Details | |
2024-08-06 06:54:39 -0500 | Rating Details | |
2024-08-06 06:39:43 -0500 | Rating Details | |
2024-08-06 05:23:57 -0500 | Rating Details | |
2024-08-06 04:24:06 -0500 | Rating Details | |
2024-08-06 03:42:59 -0500 | Rating Details | |
2024-08-06 03:14:50 -0500 | Rating Details | |
2024-08-06 03:10:41 -0500 | Rating Details | |
2024-08-05 22:32:50 -0500 | Rating Details | |
2024-08-05 17:58:38 -0500 | Rating Details | |
2024-08-05 16:29:10 -0500 | Rating Details | |
2024-08-05 16:16:59 -0500 | Rating Details | |
2024-08-05 15:56:26 -0500 | Rating Details | |
2024-08-05 11:07:50 -0500 | Rating Details | |
2024-08-05 10:59:27 -0500 | Rating Details | |
2024-08-05 09:39:38 -0500 | Rating Details | |
2024-08-05 08:18:39 -0500 | Rating Details | |
2024-08-05 08:02:50 -0500 | Rating Details | |
2024-09-17 18:35:17 -0500 | Rating Details | |
2024-10-13 08:32:55 -0500 | Rating Details |